The Bull Rankings scorecard — our quality-growth score is 73.6 / 100, built from three pillars scored 0–100: Quality 70, Growth 94, Value 61 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 19% a year next year, fading to 4% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
FIGS is a high‑growth apparel brand that has turned the scrub‑wear niche into a lifestyle juggernaut. The stock trades at P/E 45.4, the 95th percentile for Consumer Cyclical, yet our model assigns it a quality‑growth score of 73.6/100. The growth pillar scores 94, the quality pillar 70, and value sits at 61—the softest of the three but still on the cheap side of sector peers. The price is already pricing in a free‑cash‑flow growth of about 19% in year one, tapering to 4% by year ten. That starting rate is below the trailing revenue growth of 24.7%, meaning the market is slightly pessimistic about sustaining the recent acceleration.
The single sharpest argument for holding FIGS today is its growth engine: a 24.7% YoY revenue jump in the latest quarter, a robust 8.7% profit margin, and a 14% ROE. These figures demonstrate that the company is not merely riding a trend; it is expanding its product mix and customer base at a pace that outstrips the broader apparel sector. The growth pillar’s 94 score confirms that the market sees this trajectory as credible, even if the valuation multiple is high.
What the business actually is
FIGS sells scrubwear and non‑scrubwear apparel directly to healthcare professionals through its digital platform. The catalog includes scrub caps, lanyards, badge reels, bags, baseball caps, and beanies, alongside outerwear, underscrubs, footwear, compression socks, lab coats, loungewear, sports apparel, performance leggings, super‑soft pima cotton tops, vests, fleeces, and jackets. The core customer is the medical workforce, but the brand has successfully cross‑sold lifestyle items—such as fleece jackets and performance leggings—to a broader consumer base. The growth in revenue is driven primarily by the expansion of the non‑scrubwear segment, which carries higher margins and broader appeal.
Why it can (or can't) keep compounding
The moat is brand equity in a niche market that blends functionality with fashion. Healthcare professionals value durability and comfort; FIGS delivers that with a design‑first approach and a direct‑to‑consumer model that cuts out intermediaries. The 8.7% profit margin indicates that the company can squeeze more value from each dollar of sales, while a 14% ROE shows efficient use of capital. Competitors would need to replicate the brand’s cultural resonance and supply‑chain agility, a task that would take years and significant capital. The model’s quality pillar of 70 reflects these operational strengths, suggesting that returns on capital are solid and that the company can sustain its growth without diluting shareholders.
The valuation question
The market’s P/E of 45.4 places FIGS in the most expensive decile of Consumer Cyclical, yet the reverse‑DCF implied growth of 19% in year one is still below the recent 24.7% revenue growth. This mismatch signals that the price is already pricing in a slowdown. If FIGS can maintain or even accelerate its revenue growth, the current valuation would appear conservative. Conversely, if the growth rate dips below the implied 19%, the stock would be overvalued relative to its fundamentals. The 61 value score, while the softest pillar, still indicates that the stock is not the cheapest in the sector, but it is not a bargain either.
The bear case
The most compelling skeptic points to the high P/E 45.4 and the fact that the implied growth rate is lower than the recent revenue growth. If the company’s free‑cash‑flow growth stalls at the 4% level projected for year ten, the stock would be overvalued by a significant margin. A concrete signal that would confirm this scenario is a drop in the profit margin below 8% or a decrease in ROE below 14%, both of which would erode the quality pillar and undermine the growth narrative.
What would change our mind
- Revenue growth falling below 20% YoY in the next quarter would erode the growth pillar and push the implied growth rate closer to the market’s 19% assumption, tightening the valuation.
- Profit margin slipping below 8% would weaken the quality pillar, suggesting that cost pressures are eroding the business’s competitive edge.
- Debt‑to‑equity rising above 0.13 would signal financial strain, potentially limiting the company’s ability to invest in product innovation and marketing.
If any of these thresholds are breached, the current thesis would need to be revisited.